Stock Analiz

Amarin Corp. Plcuk AMRN

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$11.38Market cap $478M
Open the interactive analysis →

Amarin Corp. Plcuk (AMRN) is a healthcare company listed in the US with a market value of about $478M. In the twelve months to September 30, 2026 it had revenue of $176M and net income of -$19M, a net margin of -10.9%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is track record (0/5).

Key numbers: a price to free cash flow of 12.8, 5-year revenue growth of -19% a year, a 5-year average ROIC of -9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 69% below the current price.

About Amarin Corp. Plcuk

Amarin Corp. Plcuk is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $54M in 2014 to $214M in 2025, growth of about 13.3% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 3% over three years (dilution for shareholders). It spends 9% of revenue on research and development.

Score: 1.4 / 5

Value1/5
Future growth2/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • P/FCF below 20
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF12.8
P/S2.7
P/B1.1
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield7.8%
Shareholder yield0.0%
Intrinsic value vs. price−69%

Growth and quality

Revenue growth (1 yr)-6.6%
Revenue growth (5 yrs, per year)-19.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-20.1%
ROIC (5-yr avg.)-9.1%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$176M$214M$229M$307M$369M$583M$614M$430M$229M$181M$130M
Net income-$19M-$39M-$82M-$59M-$106M$8M-$18M-$23M-$116M-$68M-$86M
Free cash flow$37M—————-$22M-$12M-$95M-$33M-$72M
EPS (diluted)$-0.50$-0.90$-2.00$-1.50$-2.60$0.20$-0.50$-0.70$-3.90$-2.50$-4.10
Net margin-10.9%-18.2%-35.9%-19.3%-28.7%1.3%-2.9%-5.3%-50.8%-37.5%-66.4%
ROIC—-8.5%-14.6%-9.5%-13.8%1.1%-2.4%-2.9%-36.8%-128.2%-56.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $13.00, 14% above the current price; targets range from $13.00 to $13.00; the consensus rating is “none”.

Frequently asked questions

Is Amarin Corp. Plcuk stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 69% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Amarin Corp. Plcuk pay a dividend?

Not currently.

Is Amarin Corp. Plcuk a good stock to buy?

We do not give buy or sell advice. Amarin Corp. Plcuk scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.